 | • レポートコード：QFJ1-5879 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、神経変性疾患治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（免疫調節剤、インターフェロン、デカルボキシラーゼ阻害剤、ドーパミン作動薬、その他）、用途別市場規模（多発性硬化症、パーキンソン病、アルツハイマー病、脊髄性筋萎縮症、ハンチントン病、その他神経変性疾患）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・神経変性疾患治療薬の市場動向 ・企業の競争状況、市場シェア ・神経変性疾患治療薬の種類別市場規模と予測2016-2027（免疫調節剤、インターフェロン、デカルボキシラーゼ阻害剤、ドーパミン作動薬、その他） ・神経変性疾患治療薬の用途別市場規模と予測2016-2027（多発性硬化症、パーキンソン病、アルツハイマー病、脊髄性筋萎縮症、ハンチントン病、その他神経変性疾患） ・神経変性疾患治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・神経変性疾患治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・神経変性疾患治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・神経変性疾患治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・神経変性疾患治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Biogen, Inc.、Pfizer, Inc.、Novartis AG、Sanofi S.A.、Teva Pharmaceutical Industries Ltd.、UCB S.A.、F. Hoffmann- La Roche Ltd.、H. Lundbeck、Merck KGaA、GlaxoSmithKline PLC、AbbVie Inc.、Bristol Myers Squibb Company、Boehringer Ingeiheim International GmbH、Bayer AG、Eisai Co., Ltd） ・結論 |
The goal of therapeutic development for neurodegenerative disorders is to develop drugs that slow down or stop the neurodegenerative process. So-called neuroprotective, or disease-modifying, therapies would not only treat the symptoms but slow the continued loss of neurons in disease.
Market Analysis and Insights: Global Neurodegenerative Disorder Therapeutics Market
The global Neurodegenerative Disorder Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neurodegenerative Disorder Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neurodegenerative Disorder Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neurodegenerative Disorder Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neurodegenerative Disorder Therapeutics market.
Global Neurodegenerative Disorder Therapeutics Scope and Market Size
Neurodegenerative Disorder Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neurodegenerative Disorder Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Immunomodulators
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others
Segment by Application
Multiple Sclerosis
Parkinson’S Disease
Alzheimer’S Disease
Spinal Muscular Atrophy
Huntington Disease
Other Neurodegenerative Disorders
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Biogen, Inc.
Pfizer, Inc.
Novartis AG
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
UCB S.A.
F. Hoffmann- La Roche Ltd.
H. Lundbeck
Merck KGaA
GlaxoSmithKline PLC
AbbVie Inc.
Bristol Myers Squibb Company
Boehringer Ingeiheim International GmbH
Bayer AG
Eisai Co., Ltd
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Immunomodulators
1.2.3 Interferons
1.2.4 Decarboxylase Inhibitors
1.2.5 Dopamine Agonists
1.2.6 Others
1.3 Market by Application
1.3.1 Global Neurodegenerative Disorder Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Multiple Sclerosis
1.3.3 Parkinson’S Disease
1.3.4 Alzheimer’S Disease
1.3.5 Spinal Muscular Atrophy
1.3.6 Huntington Disease
1.3.7 Other Neurodegenerative Disorders
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Neurodegenerative Disorder Therapeutics Market Perspective (2016-2027)
2.2 Neurodegenerative Disorder Therapeutics Growth Trends by Regions
2.2.1 Neurodegenerative Disorder Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Neurodegenerative Disorder Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Neurodegenerative Disorder Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Neurodegenerative Disorder Therapeutics Industry Dynamic
2.3.1 Neurodegenerative Disorder Therapeutics Market Trends
2.3.2 Neurodegenerative Disorder Therapeutics Market Drivers
2.3.3 Neurodegenerative Disorder Therapeutics Market Challenges
2.3.4 Neurodegenerative Disorder Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Disorder Therapeutics Players by Revenue
3.1.1 Global Top Neurodegenerative Disorder Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Neurodegenerative Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Neurodegenerative Disorder Therapeutics Revenue
3.4 Global Neurodegenerative Disorder Therapeutics Market Concentration Ratio
3.4.1 Global Neurodegenerative Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disorder Therapeutics Revenue in 2020
3.5 Neurodegenerative Disorder Therapeutics Key Players Head office and Area Served
3.6 Key Players Neurodegenerative Disorder Therapeutics Product Solution and Service
3.7 Date of Enter into Neurodegenerative Disorder Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurodegenerative Disorder Therapeutics Breakdown Data by Type
4.1 Global Neurodegenerative Disorder Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Type (2022-2027)
5 Neurodegenerative Disorder Therapeutics Breakdown Data by Application
5.1 Global Neurodegenerative Disorder Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Neurodegenerative Disorder Therapeutics Market Size (2016-2027)
6.2 North America Neurodegenerative Disorder Therapeutics Market Size by Type
6.2.1 North America Neurodegenerative Disorder Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Neurodegenerative Disorder Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Neurodegenerative Disorder Therapeutics Market Size by Type (2016-2027)
6.3 North America Neurodegenerative Disorder Therapeutics Market Size by Application
6.3.1 North America Neurodegenerative Disorder Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Neurodegenerative Disorder Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Neurodegenerative Disorder Therapeutics Market Size by Application (2016-2027)
6.4 North America Neurodegenerative Disorder Therapeutics Market Size by Country
6.4.1 North America Neurodegenerative Disorder Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Neurodegenerative Disorder Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Neurodegenerative Disorder Therapeutics Market Size (2016-2027)
7.2 Europe Neurodegenerative Disorder Therapeutics Market Size by Type
7.2.1 Europe Neurodegenerative Disorder Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Neurodegenerative Disorder Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Neurodegenerative Disorder Therapeutics Market Size by Type (2016-2027)
7.3 Europe Neurodegenerative Disorder Therapeutics Market Size by Application
7.3.1 Europe Neurodegenerative Disorder Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Neurodegenerative Disorder Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Neurodegenerative Disorder Therapeutics Market Size by Application (2016-2027)
7.4 Europe Neurodegenerative Disorder Therapeutics Market Size by Country
7.4.1 Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Type
8.2.1 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Application
8.3.1 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region
8.4.1 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Neurodegenerative Disorder Therapeutics Market Size (2016-2027)
9.2 Latin America Neurodegenerative Disorder Therapeutics Market Size by Type
9.2.1 Latin America Neurodegenerative Disorder Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Neurodegenerative Disorder Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Neurodegenerative Disorder Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Neurodegenerative Disorder Therapeutics Market Size by Application
9.3.1 Latin America Neurodegenerative Disorder Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Neurodegenerative Disorder Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Neurodegenerative Disorder Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Neurodegenerative Disorder Therapeutics Market Size by Country
9.4.1 Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Type
10.2.1 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Application
10.3.1 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country
10.4.1 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Biogen, Inc.
11.1.1 Biogen, Inc. Company Details
11.1.2 Biogen, Inc. Business Overview
11.1.3 Biogen, Inc. Neurodegenerative Disorder Therapeutics Introduction
11.1.4 Biogen, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021)
11.1.5 Biogen, Inc. Recent Development
11.2 Pfizer, Inc.
11.2.1 Pfizer, Inc. Company Details
11.2.2 Pfizer, Inc. Business Overview
11.2.3 Pfizer, Inc. Neurodegenerative Disorder Therapeutics Introduction
11.2.4 Pfizer, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021)
11.2.5 Pfizer, Inc. Recent Development
11.3 Novartis AG
11.3.1 Novartis AG Company Details
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Neurodegenerative Disorder Therapeutics Introduction
11.3.4 Novartis AG Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021)
11.3.5 Novartis AG Recent Development
11.4 Sanofi S.A.
11.4.1 Sanofi S.A. Company Details
11.4.2 Sanofi S.A. Business Overview
11.4.3 Sanofi S.A. Neurodegenerative Disorder Therapeutics Introduction
11.4.4 Sanofi S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021)
11.4.5 Sanofi S.A. Recent Development
11.5 Teva Pharmaceutical Industries Ltd.
11.5.1 Teva Pharmaceutical Industries Ltd. Company Details
11.5.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.5.3 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Introduction
11.5.4 Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021)
11.5.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.6 UCB S.A.
11.6.1 UCB S.A. Company Details
11.6.2 UCB S.A. Business Overview
11.6.3 UCB S.A. Neurodegenerative Disorder Therapeutics Introduction
11.6.4 UCB S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021)
11.6.5 UCB S.A. Recent Development
11.7 F. Hoffmann- La Roche Ltd.
11.7.1 F. Hoffmann- La Roche Ltd. Company Details
11.7.2 F. Hoffmann- La Roche Ltd. Business Overview
11.7.3 F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Introduction
11.7.4 F. Hoffmann- La Roche Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021)
11.7.5 F. Hoffmann- La Roche Ltd. Recent Development
11.8 H. Lundbeck
11.8.1 H. Lundbeck Company Details
11.8.2 H. Lundbeck Business Overview
11.8.3 H. Lundbeck Neurodegenerative Disorder Therapeutics Introduction
11.8.4 H. Lundbeck Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021)
11.8.5 H. Lundbeck Recent Development
11.9 Merck KGaA
11.9.1 Merck KGaA Company Details
11.9.2 Merck KGaA Business Overview
11.9.3 Merck KGaA Neurodegenerative Disorder Therapeutics Introduction
11.9.4 Merck KGaA Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021)
11.9.5 Merck KGaA Recent Development
11.10 GlaxoSmithKline PLC
11.10.1 GlaxoSmithKline PLC Company Details
11.10.2 GlaxoSmithKline PLC Business Overview
11.10.3 GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Introduction
11.10.4 GlaxoSmithKline PLC Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021)
11.10.5 GlaxoSmithKline PLC Recent Development
11.11 AbbVie Inc.
11.11.1 AbbVie Inc. Company Details
11.11.2 AbbVie Inc. Business Overview
11.11.3 AbbVie Inc. Neurodegenerative Disorder Therapeutics Introduction
11.11.4 AbbVie Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021)
11.11.5 AbbVie Inc. Recent Development
11.12 Bristol Myers Squibb Company
11.12.1 Bristol Myers Squibb Company Company Details
11.12.2 Bristol Myers Squibb Company Business Overview
11.12.3 Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Introduction
11.12.4 Bristol Myers Squibb Company Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021)
11.12.5 Bristol Myers Squibb Company Recent Development
11.13 Boehringer Ingeiheim International GmbH
11.13.1 Boehringer Ingeiheim International GmbH Company Details
11.13.2 Boehringer Ingeiheim International GmbH Business Overview
11.13.3 Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Introduction
11.13.4 Boehringer Ingeiheim International GmbH Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021)
11.13.5 Boehringer Ingeiheim International GmbH Recent Development
11.14 Bayer AG
11.14.1 Bayer AG Company Details
11.14.2 Bayer AG Business Overview
11.14.3 Bayer AG Neurodegenerative Disorder Therapeutics Introduction
11.14.4 Bayer AG Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021)
11.14.5 Bayer AG Recent Development
11.15 Eisai Co., Ltd
11.15.1 Eisai Co., Ltd Company Details
11.15.2 Eisai Co., Ltd Business Overview
11.15.3 Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Introduction
11.15.4 Eisai Co., Ltd Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021)
11.15.5 Eisai Co., Ltd Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Immunomodulators
Table 3. Key Players of Interferons
Table 4. Key Players of Decarboxylase Inhibitors
Table 5. Key Players of Dopamine Agonists
Table 6. Key Players of Others
Table 7. Global Neurodegenerative Disorder Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Neurodegenerative Disorder Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Neurodegenerative Disorder Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Neurodegenerative Disorder Therapeutics Market Share by Regions (2016-2021)
Table 11. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Neurodegenerative Disorder Therapeutics Market Share by Regions (2022-2027)
Table 13. Neurodegenerative Disorder Therapeutics Market Trends
Table 14. Neurodegenerative Disorder Therapeutics Market Drivers
Table 15. Neurodegenerative Disorder Therapeutics Market Challenges
Table 16. Neurodegenerative Disorder Therapeutics Market Restraints
Table 17. Global Neurodegenerative Disorder Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Neurodegenerative Disorder Therapeutics Market Share by Players (2016-2021)
Table 19. Global Top Neurodegenerative Disorder Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurodegenerative Disorder Therapeutics as of 2020)
Table 20. Ranking of Global Top Neurodegenerative Disorder Therapeutics Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Neurodegenerative Disorder Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Neurodegenerative Disorder Therapeutics Product Solution and Service
Table 24. Date of Enter into Neurodegenerative Disorder Therapeutics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Neurodegenerative Disorder Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Type (2016-2021)
Table 28. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Neurodegenerative Disorder Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Application (2016-2021)
Table 32. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Neurodegenerative Disorder Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Neurodegenerative Disorder Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Neurodegenerative Disorder Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Neurodegenerative Disorder Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Neurodegenerative Disorder Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Neurodegenerative Disorder Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Neurodegenerative Disorder Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Neurodegenerative Disorder Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Neurodegenerative Disorder Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Neurodegenerative Disorder Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Neurodegenerative Disorder Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Neurodegenerative Disorder Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Neurodegenerative Disorder Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Neurodegenerative Disorder Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 64. Biogen, Inc. Company Details
Table 65. Biogen, Inc. Business Overview
Table 66. Biogen, Inc. Neurodegenerative Disorder Therapeutics Product
Table 67. Biogen, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 68. Biogen, Inc. Recent Development
Table 69. Pfizer, Inc. Company Details
Table 70. Pfizer, Inc. Business Overview
Table 71. Pfizer, Inc. Neurodegenerative Disorder Therapeutics Product
Table 72. Pfizer, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 73. Pfizer, Inc. Recent Development
Table 74. Novartis AG Company Details
Table 75. Novartis AG Business Overview
Table 76. Novartis AG Neurodegenerative Disorder Therapeutics Product
Table 77. Novartis AG Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 78. Novartis AG Recent Development
Table 79. Sanofi S.A. Company Details
Table 80. Sanofi S.A. Business Overview
Table 81. Sanofi S.A. Neurodegenerative Disorder Therapeutics Product
Table 82. Sanofi S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 83. Sanofi S.A. Recent Development
Table 84. Teva Pharmaceutical Industries Ltd. Company Details
Table 85. Teva Pharmaceutical Industries Ltd. Business Overview
Table 86. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Product
Table 87. Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 88. Teva Pharmaceutical Industries Ltd. Recent Development
Table 89. UCB S.A. Company Details
Table 90. UCB S.A. Business Overview
Table 91. UCB S.A. Neurodegenerative Disorder Therapeutics Product
Table 92. UCB S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 93. UCB S.A. Recent Development
Table 94. F. Hoffmann- La Roche Ltd. Company Details
Table 95. F. Hoffmann- La Roche Ltd. Business Overview
Table 96. F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Product
Table 97. F. Hoffmann- La Roche Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 98. F. Hoffmann- La Roche Ltd. Recent Development
Table 99. H. Lundbeck Company Details
Table 100. H. Lundbeck Business Overview
Table 101. H. Lundbeck Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 102. H. Lundbeck Recent Development
Table 103. Merck KGaA Company Details
Table 104. Merck KGaA Business Overview
Table 105. Merck KGaA Neurodegenerative Disorder Therapeutics Product
Table 106. Merck KGaA Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 107. Merck KGaA Recent Development
Table 108. GlaxoSmithKline PLC Company Details
Table 109. GlaxoSmithKline PLC Business Overview
Table 110. GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Product
Table 111. GlaxoSmithKline PLC Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 112. GlaxoSmithKline PLC Recent Development
Table 113. AbbVie Inc. Company Details
Table 114. AbbVie Inc. Business Overview
Table 115. AbbVie Inc. Neurodegenerative Disorder Therapeutics Product
Table 116. AbbVie Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 117. AbbVie Inc. Recent Development
Table 118. Bristol Myers Squibb Company Company Details
Table 119. Bristol Myers Squibb Company Business Overview
Table 120. Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Product
Table 121. Bristol Myers Squibb Company Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 122. Bristol Myers Squibb Company Recent Development
Table 123. Boehringer Ingeiheim International GmbH Company Details
Table 124. Boehringer Ingeiheim International GmbH Business Overview
Table 125. Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Product
Table 126. Boehringer Ingeiheim International GmbH Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 127. Boehringer Ingeiheim International GmbH Recent Development
Table 128. Bayer AG Company Details
Table 129. Bayer AG Business Overview
Table 130. Bayer AG Neurodegenerative Disorder Therapeutics Product
Table 131. Bayer AG Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 132. Bayer AG Recent Development
Table 133. Eisai Co., Ltd Company Details
Table 134. Eisai Co., Ltd Business Overview
Table 135. Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Product
Table 136. Eisai Co., Ltd Revenue in Neurodegenerative Disorder Therapeutics Business (2016-2021) & (US$ Million)
Table 137. Eisai Co., Ltd Recent Development
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurodegenerative Disorder Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Immunomodulators Features
Figure 3. Interferons Features
Figure 4. Decarboxylase Inhibitors Features
Figure 5. Dopamine Agonists Features
Figure 6. Others Features
Figure 7. Global Neurodegenerative Disorder Therapeutics Market Share by Application: 2020 VS 2027
Figure 8. Multiple Sclerosis Case Studies
Figure 9. Parkinson'S Disease Case Studies
Figure 10. Alzheimer'S Disease Case Studies
Figure 11. Spinal Muscular Atrophy Case Studies
Figure 12. Huntington Disease Case Studies
Figure 13. Other Neurodegenerative Disorders Case Studies
Figure 14. Neurodegenerative Disorder Therapeutics Report Years Considered
Figure 15. Global Neurodegenerative Disorder Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 16. Global Neurodegenerative Disorder Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 17. Global Neurodegenerative Disorder Therapeutics Market Share by Regions: 2020 VS 2027
Figure 18. Global Neurodegenerative Disorder Therapeutics Market Share by Regions (2022-2027)
Figure 19. Global Neurodegenerative Disorder Therapeutics Market Share by Players in 2020
Figure 20. Global Top Neurodegenerative Disorder Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurodegenerative Disorder Therapeutics as of 2020
Figure 21. The Top 10 and 5 Players Market Share by Neurodegenerative Disorder Therapeutics Revenue in 2020
Figure 22. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Type (2016-2021)
Figure 23. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Type (2022-2027)
Figure 24. North America Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. North America Neurodegenerative Disorder Therapeutics Market Share by Type (2016-2027)
Figure 26. North America Neurodegenerative Disorder Therapeutics Market Share by Application (2016-2027)
Figure 27. North America Neurodegenerative Disorder Therapeutics Market Share by Country (2016-2027)
Figure 28. United States Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Canada Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Europe Neurodegenerative Disorder Therapeutics Market Share by Type (2016-2027)
Figure 32. Europe Neurodegenerative Disorder Therapeutics Market Share by Application (2016-2027)
Figure 33. Europe Neurodegenerative Disorder Therapeutics Market Share by Country (2016-2027)
Figure 34. Germany Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. France Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. U.K. Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Italy Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Russia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Nordic Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Share by Type (2016-2027)
Figure 42. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Share by Application (2016-2027)
Figure 43. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Share by Region (2016-2027)
Figure 44. China Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Japan Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. South Korea Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Southeast Asia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. India Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Australia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Latin America Neurodegenerative Disorder Therapeutics Market Share by Type (2016-2027)
Figure 52. Latin America Neurodegenerative Disorder Therapeutics Market Share by Application (2016-2027)
Figure 53. Latin America Neurodegenerative Disorder Therapeutics Market Share by Country (2016-2027)
Figure 54. Mexico Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Brazil Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Share by Type (2016-2027)
Figure 58. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Share by Application (2016-2027)
Figure 59. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Share by Country (2016-2027)
Figure 60. Turkey Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Saudi Arabia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. UAE Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 63. Biogen, Inc. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2016-2021)
Figure 64. Pfizer, Inc. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2016-2021)
Figure 65. Novartis AG Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2016-2021)
Figure 66. Sanofi S.A. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2016-2021)
Figure 67. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2016-2021)
Figure 68. UCB S.A. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2016-2021)
Figure 69. F. Hoffmann- La Roche Ltd. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2016-2021)
Figure 70. H. Lundbeck Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2016-2021)
Figure 71. Merck KGaA Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2016-2021)
Figure 72. GlaxoSmithKline PLC Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2016-2021)
Figure 73. AbbVie Inc. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2016-2021)
Figure 74. Bristol Myers Squibb Company Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2016-2021)
Figure 75. Boehringer Ingeiheim International GmbH Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2016-2021)
Figure 76. Bayer AG Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2016-2021)
Figure 77. Eisai Co., Ltd Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2016-2021)
Figure 78. Bottom-up and Top-down Approaches for This Report
Figure 79. Data Triangulation
Figure 80. Key Executives Interviewed
世界の神経変性疾患治療市場規模・現状・予測（2021年-2027年） Neurodegenerative diseases largely refer to incremental damage to nerve cells in different parts of the body. These ailments, including Alzheimer’s disease, Parkinson’s disease, ADHD, and ALS, can result in loss of memory and cognitive control. While cures for such conditions are very limited, over …- 世界のパーキンソン病治療市場規模・現状・予測（2021年-2027年） Parkinson’s disease (PD) is a chronic and progressive disease, considered an idiopathic form, and accounts for roughly 80% of the cases of Parkinsonism—neurological disorders that lead to movement problems. While the exact cause of Parkinson’s disease is unknown, it may include a number of factors s…
- 世界の心的外傷後ストレス障害治療薬市場規模・現状・予測（2021年-2027年） The main treatments for post-traumatic stress disorder (PTSD) are psychological therapies and medication. Market Analysis and Insights: Global Post-Traumatic Stress Disorder Therapeutics Market The global Post-Traumatic Stress Disorder Therapeutics market size is projected to reach US$ XX million by…
- 世界のCDKL5欠乏症（CDD）市場規模・現状・予測（2021年-2027年） CDKL5 deficiency disorder (CDD) is a rare developmental epileptic encephalopathy (DEE), X-linked genetic condition which results in early-onset, difficult to control seizures and severe neuro-developmental impairment. CDKL5 stands for cyclin-dependent kinase-like 5 and mutations in this gene were fi…
- 世界の季節性情動障害治療薬市場規模・現状・予測（2021年-2027年） Seasonal affective disorder (SAD) is a mood disorder subset in which people who have normal mental health throughout most of the year exhibit depressive symptoms at the same time each year, most commonly in the winter. Common symptoms include sleeping too much, having little to no energy, and overea…